Skip to main content
Premium Trial:

Request an Annual Quote

AstraZeneca Expands Licensing Deal With InforSense for KDE Software

NEW YORK, Dec. 15 (GenomeWeb News) - InforSense and AstraZeneca have extended a previously existing licensing agreement, the firms said today.

 

As part of a new multi-year global licensing deal, scientists at AstraZeneca R&D sites will use InforSense's workflow-based integrative analytics software, InforSense KDE, in their core drug-discovery programs. 

 

AstraZeneca has used InforSense technology since 2001, the companies said.  The new deal expands access to InforSense KDE across AstraZeneca's R&D organization for integrative biology, chemistry, and text-mining applications. 

 

Financial terms of the agreement were not disclosed.